It is suggested that BRAFV600E mutant D-NEC, for which there is currently no targeted treatment options available, might benefit from combination therapy comprising a BRAF inhibitor and standard chemotherapy agent. This evidence concerns the gene BRAF and neuroendocrine carcinoma.